Principles of Good Clinical Practice

Principles of Good Clinical Practice provide the ethical, scientific and quality foundation for clinical trials involving human participants. They are designed to protect the rights, safety and well-being of trial participants while supporting the generation of reliable clinical trial results.

The modern international framework is provided by the International Council for Harmonisation (ICH) E6(R3) Guideline for Good Clinical Practice. The guideline reflects the continuing evolution of clinical research and places greater emphasis on quality by design, proportionate approaches, participant protection, reliable results and the appropriate use of technology.

Table of Contents

Principles of Good Clinical Practice – Role of the FDA

In the United States, the Food and Drug Administration (FDA), an agency within the Department of Health and Human Services, regulates clinical investigations involving products subject to FDA requirements.

FDA oversight of clinical trials is intended to protect the rights, safety and welfare of participants and help ensure that clinical trial data used in regulatory decision-making are reliable.

FDA requirements relating to clinical investigations include areas such as:

Protection of human participants
Institutional Review Boards
Investigational New Drug applications
Informed consent
Investigator and sponsor responsibilities
Clinical trial records
Safety reporting
Electronic records and systems
Regulatory inspections

ICH GCP provides an internationally harmonised framework, while clinical trials must also comply with applicable national and regional laws and regulations.

What Is Good Clinical Practice?

Good Clinical Practice is an international ethical, scientific and quality standard for clinical trials involving human participants.

GCP applies throughout the clinical trial lifecycle, including activities such as planning, initiating, conducting, recording, oversight, evaluation, analysis and reporting.

Conducting trials according to GCP helps ensure that:

The rights, safety and well-being of participants are protected
Trials are ethically and scientifically sound
Informed consent is appropriately obtained
Responsibilities are clearly defined
Trial processes are appropriately controlled
Clinical trial information is reliable
Results can support appropriate scientific and regulatory evaluation

Modern GCP encourages approaches that are proportionate to the risks of the trial and the importance of the information being collected.

Historical Development of Good Clinical Practice

Modern Good Clinical Practice developed from decades of experience in medicine, pharmaceutical regulation and research ethics.

Several historical events demonstrated the need for stronger controls over drug development and human research.

One important event was the 1937 elixir sulfanilamide tragedy in the United States. More than 100 people died after consuming a preparation containing diethylene glycol.

The tragedy contributed to enactment of the Federal Food, Drug, and Cosmetic Act of 1938, which substantially strengthened federal authority over drug safety.

Another important event was the thalidomide tragedy of the late 1950s and early 1960s. Thalidomide use during pregnancy was associated with severe congenital abnormalities in thousands of children internationally.

These and other events contributed to stronger requirements for demonstrating the safety and effectiveness of medicines and to the development of ethical and regulatory standards for clinical research.

The Declaration of Helsinki

The World Medical Association’s Declaration of Helsinki is an important international statement of ethical principles for medical research involving human participants.

It addresses fundamental concepts such as:

Protection of research participants
Scientific integrity
Assessment of risks and benefits
Independent ethical review
Informed consent
Privacy and confidentiality
Protection of vulnerable individuals and groups
Research protocols
Registration and dissemination of research
Post-trial considerations where applicable

ICH E6(R3) recognizes that GCP principles have their origin in the Declaration of Helsinki.

Clinical research must also comply with applicable laws and regulatory requirements in the countries where the research is conducted.

International Council for Harmonisation

The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, commonly known as ICH, brings together regulatory authorities and the pharmaceutical industry to develop harmonised technical guidelines for pharmaceutical development and registration.

ICH originated in 1990 as the International Conference on Harmonisation.

In 2015, it underwent organizational reform and became the International Council for Harmonisation, establishing a broader international governance structure.

ICH develops guidelines across four major areas:

Quality
Safety
Efficacy
Multidisciplinary topics

Good Clinical Practice is addressed primarily through the ICH E6 guideline within the Efficacy series.

Evolution from ICH E6(R2) to E6(R3)

Clinical research has changed considerably since the original ICH E6 guideline was introduced in the 1990s.

Trials increasingly use electronic systems, remote processes, decentralized elements, new data sources, advanced analytics and more complex trial designs.

ICH E6(R3) was therefore developed to modernize the GCP framework while maintaining its central focus on participant protection and reliable trial results.

The current ICH Good Clinical Practice guideline provides the international E6(R3) framework for the conduct of clinical trials.

Important themes in E6(R3) include:

Quality by design
Proportionate and risk-based approaches
Identification of factors critical to trial quality
Clear roles and responsibilities
Appropriate oversight
Participant-focused trial design
Fit-for-purpose systems and processes
Reliable trial information
Appropriate use of technology
Flexibility for different trial designs and data sources

The objective is not simply to add more procedures. Instead, organizations should focus their efforts and resources on activities that are important to participant protection and the reliability of trial results.

Principles of ICH E6(R3) Good Clinical Practice

ICH E6(R3) organizes Good Clinical Practice around modern principles applicable across different types of clinical trials.

The following concepts summarize the major principles.

1. Ethical Conduct of Clinical Trials

Clinical trials should be conducted according to ethical principles that have their origin in the Declaration of Helsinki and are consistent with GCP and applicable regulatory requirements.

Ethical considerations should remain central throughout the trial lifecycle.

2. Participant Rights, Safety and Well-being

The rights, safety and well-being of trial participants are fundamental considerations and should prevail over the interests of science and society.

Risks and inconveniences should be considered in relation to anticipated benefits and the importance of the knowledge expected from the trial.

3. Informed Consent

Participation in a clinical trial should be voluntary.

Potential participants should receive appropriate information about the trial and provide informed consent before participating, except where applicable regulatory and ethical provisions permit otherwise.

The consent process should support participants’ understanding and ability to make an informed decision.

4. Independent Ethical Review

Clinical trials should undergo independent review by an Institutional Review Board or Independent Ethics Committee, as applicable.

Ethical review provides an important safeguard for participant rights, safety and well-being.

5. Scientific Soundness

Clinical trials should be scientifically sound and based on sufficient current scientific knowledge and appropriate information about the investigational product.

The trial should be designed to answer meaningful research questions and generate reliable results.

6. Qualified Individuals

Individuals involved in clinical trials should be appropriately qualified through education, training and experience to perform their assigned activities.

Responsibilities should be clearly assigned and understood.

7. Quality by Design

Quality should be built into the scientific and operational design of a clinical trial rather than relying only on retrospective checking.

Factors that are critical to trial quality should be identified prospectively and appropriately managed.

8. Proportionate and Risk-Based Approaches

Trial processes should be proportionate to the risks to participants and the importance of the information being collected.

Resources should focus on activities and information that are critical to participant protection and reliable trial results.

This approach can help avoid unnecessary complexity and burden while maintaining appropriate quality.

9. Reliable Trial Data and Results

Systems and processes used to generate, record, manage and analyse trial information should support reliable results.

Data should be sufficiently accurate, complete and traceable for their intended purpose.

Appropriate controls should be applied according to the importance of the data and associated risks.

10. Participant-Focused Trial Design

Clinical trial design and conduct should consider the perspectives and needs of participants where appropriate.

Reducing unnecessary burden can improve the feasibility of participation and support effective trial conduct.

11. Investigational Product Management

Investigational products should be manufactured, handled, stored and used according to applicable Good Manufacturing Practice requirements and the approved trial protocol.

Appropriate accountability and control should be maintained throughout the trial.

12. Clear Roles and Responsibilities

The roles, responsibilities and activities of sponsors, investigators and other parties should be clearly defined and documented.

Activities may be delegated or transferred where appropriate, but responsibility and oversight should remain consistent with applicable GCP requirements.

13. Appropriate Use of Technology

Technologies used in clinical trials should be fit for their intended purpose.

Electronic systems, digital technologies and other tools should support participant protection and reliable trial information without introducing unnecessary complexity or unmanaged risks.

Quality by Design in Clinical Trials

Quality by design is one of the important themes of modern GCP.

Rather than attempting to eliminate every possible operational error, trial planning should identify the factors that are critical to achieving meaningful trial objectives and protecting participants.

These factors may relate to:

Eligibility criteria
Informed consent
Randomisation
Important endpoints
Safety assessments
Investigational product management
Critical trial data
Protocol adherence
Participant retention

Appropriate controls can then be designed around these critical factors.

Risk-Based Quality Management

Risk-based quality management applies systematic consideration to risks that could affect participant protection or the reliability of trial results.

Risk management may include:

Risk identification
Risk evaluation
Risk control
Risk communication
Risk review
Appropriate documentation

The intensity of oversight, monitoring and other quality activities should be proportionate to identified risks and the importance of trial activities and data.

Technology and Modern Clinical Trials

Modern clinical trials increasingly rely on computerized systems and digital technologies.

Examples include:

Electronic data capture
Electronic informed consent
Electronic clinical outcome assessments
Digital health technologies
Remote data collection
Centralised monitoring
Electronic trial master files
Interactive response technologies
Electronic safety-reporting systems

Technology should be selected and managed according to its intended purpose and the risks associated with its use.

Systems supporting important trial activities or data should have appropriate controls for areas such as access, security, data integrity, traceability and reliability.

Responsibilities and Oversight

Clinical research often involves sponsors, investigators, contract research organizations, laboratories, technology providers and other service providers.

Activities can be delegated or transferred, but appropriate oversight remains essential.

Sponsors should maintain appropriate oversight of transferred activities, while investigators should maintain appropriate oversight of individuals or parties performing trial-related activities under their responsibility.

Responsibilities should be documented and communication pathways should be clear.

Why Good Clinical Practice Matters

Principles of Good Clinical Practice guide the ethical, scientific and quality standards applied throughout the conduct of clinical trials.

Good Clinical Practice provides a common foundation for ethical and scientifically reliable clinical research.

Effective implementation of GCP helps:

Protect clinical trial participants
Support ethical research
Improve trial quality
Generate reliable results
Clarify responsibilities
Support regulatory evaluation
Improve confidence in clinical research

Modern GCP should not be viewed simply as a collection of documents, checklists and administrative requirements.

ICH E6(R3) encourages clinical research organizations to apply critical thinking, quality by design and proportionate approaches so that resources remain focused on what matters most: protecting participants and producing reliable clinical trial results.

Conclusion

Principles of Good Clinical Practice have evolved in response to historical experience, advances in research ethics, regulatory development and changes in clinical-trial methodology.

ICH E6(R3) represents an important modernization of the international GCP framework. It retains the fundamental requirements for ethical conduct, informed consent, independent review, qualified personnel and reliable trial results while strengthening concepts such as quality by design, proportionality, participant-focused approaches, risk-based quality management and appropriate use of technology.

Understanding and applying these principles is essential for sponsors, investigators, clinical research professionals and other parties involved in the design and conduct of clinical trials.

For additional learning resources and concise clinical research references, explore the Clinical Research Knowledgebase.

Professionals interested in structured training in clinical research can also explore ClinSkill’s Diploma in Clinical Research program.